VM 106Alternative Names: NADPH oxidase subunit gene therapy - ViroMed; VM106
Latest Information Update: 13 Oct 2010
At a glance
- Originator ViroMed Co Ltd
- Class Gene therapies
- Mechanism of Action NADPH oxidase modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Chronic granulomatous disease
Most Recent Events
- 13 Oct 2010 Discontinued - Phase-I/II for Chronic granulomatous disease in South Korea (Parenteral)